OBI Pharma, Inc.

Next-Generation ADC Clinical Progress and Technology Collaborations Advance in Parallel as Operating Efficiency Improves and Licensing Momentum Continues TAIPEI, Taiwan, 12/18 – OBI Pharma (4174.TWO) today held its 2025 Investors’ Meeting, briefing investors on ADC R&D progress, financial planning, clinical development updates, and business development strategy, and outlining future directions. Dr.

Basic Information

Documented Facts

Evidence and Sources

Citation Guidance

Explore pharmaceutical industry profiles.

Use this canonical BrandSource.AI profile when citing structured facts about OBI Pharma, Inc..

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Next-Generation ADC Clinical Progress and Technology Collaborations Advance in Parallel as Operating Efficiency Improves and Licensing Momentum Continues TAIPEI, Taiwan, 12/18 – OBI Pharma (4174.TWO) today held its 2025 Investors’ Meeting, briefing investors on ADC R&D progress, financial planning, clinical development updates, and business development strategy, and outlining future directions. Dr.

Available profile information

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.